Lewes, DE -- (SBWIRE) -- 09/16/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Axa SA (ADR)(OTCMKTS:AXAHY), HRT PARTICIPACOES EM(OTCMKTS:HRTPY), Advaxis, Inc.(OTCBB:ADXS), STELLAR BIOTECH INC(OTCMKTS:SBOTF).
Axa SA (ADR)(OTCMKTS:AXAHY) ended lower -0.24% and complete the day at $23.61. The total number of shares changed hands during the day was 72,642. After opening at $23.37, the stock hit as high as $23.65. However, it traded between $14.50 and $24.17 over the last twelve months.
AXA Group, through its subsidiaries, provides insurance and asset management services. Its Life & Savings segment offers term life, whole life, universal life, endowment, deferred and immediate annuities, and other investment-based products
Has AXAHY Found The Bottom and Ready To Move Up? Find Out Here
HRT PARTICIPACOES EM(OTCMKTS:HRTPY) closed yesterday at $0.240, a +9.09% increase. Around 1.20 million shares were traded, beating an-average trading volume of 1.01 million shares. The company is now valued at around $129.91 million.
HRT Participações em Petróleo S.A., through its subsidiaries, engages in the exploration, development, production, distribution, and sale of oil and natural gas. It is also involved in the import, export, refining, sale, and distribution of oil, natural gas, fuel, and oil by-products; and generation, sale, and distribution of electric power.
For How Long HRTPY Gloss will Attract Investors? Find out via this report
Advaxis, Inc.(OTCBB:ADXS) moved -8.07 percent lower at $6.15 and traded between $6.10 and $6.74 after opening the day at $6.40. Its performance over the last five days remained 50%, which stands at 98.39% for a month. Going back further than one month, 1-year performance after recent close was 64%.
Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases.
Why Should Investors Buy ADXS After the Recent Fall? Just Go Here and Find Out
STELLAR BIOTECH INC(OTCMKTS:SBOTF) shares rose, gaining +3.64 percent to close at $1.54. The stock is up around 432.87% this year and 411.63% for the last 12 months. Around 218,266 shares changed hands yesterday, lower from an-average trading volume of 359,815 shares.
Stellar Biotechnologies, Inc. produces and markets keyhole limpet hemocyanin (KLH), as well as develops technology related to the culture and production of KLH and subunit KLH formulations in the United States and Europe
Why Should Investors Buy SBOTF After The Recent Gain? Just Go Here and Find Out
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)